Adaptimmune Therapeutics PLC (ADAP)
0.6366
-0.03
(-4.23%)
USD |
NASDAQ |
Nov 21, 16:00
0.6132
-0.02
(-3.68%)
After-Hours: 06:09
Adaptimmune Therapeutics Revenue (Quarterly): 40.90M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.90M |
| June 30, 2024 | 128.23M |
| March 31, 2024 | 5.678M |
| December 31, 2023 | 0.231M |
| September 30, 2023 | 7.319M |
| June 30, 2023 | 5.13M |
| March 31, 2023 | 47.60M |
| December 31, 2022 | 11.03M |
| September 30, 2022 | 7.007M |
| June 30, 2022 | 5.538M |
| March 31, 2022 | 3.575M |
| December 31, 2021 | 1.417M |
| September 30, 2021 | 1.203M |
| June 30, 2021 | 3.095M |
| March 31, 2021 | 0.434M |
| December 31, 2020 | 1.502M |
| September 30, 2020 | 1.193M |
| June 30, 2020 | 0.502M |
| March 31, 2020 | 0.761M |
| Date | Value |
|---|---|
| December 31, 2019 | 0.728M |
| September 30, 2019 | 0.237M |
| June 30, 2019 | 0.157M |
| March 31, 2019 | |
| December 31, 2018 | 1.479M |
| September 30, 2018 | 40.79M |
| June 30, 2018 | 9.038M |
| March 31, 2018 | 8.196M |
| December 31, 2017 | 4.27M |
| September 30, 2017 | 27.18M |
| June 30, 2017 | 3.521M |
| March 31, 2017 | 2.857M |
| December 31, 2016 | 8.536M |
| September 30, 2016 | 2.416M |
| June 30, 2016 | 0.328M |
| March 31, 2016 | 2.918M |
| September 30, 2015 | 3.940M |
| December 31, 2014 | 2.268M |
| September 30, 2014 | 1.533M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.231M
Minimum
Dec 2023
128.23M
Maximum
Jun 2024
13.65M
Average
3.335M
Median
Revenue (Quarterly) Benchmarks
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.62M |
| Total Expenses (Quarterly) | 55.58M |
| EPS Diluted (Quarterly) | -0.06 |
| Enterprise Value | 26.67M |
| Profit Margin (Quarterly) | -43.07% |
| Earnings Yield | -28.28% |
| Normalized Earnings Yield | -28.28 |